In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer.
Patients over 18 years old
Patients can remain in a stationary position on the treatment bed for 1-1.5 hours
ECOG score 0-1
Pathological diagnosis of colon adenocarcinoma, clinical stage cT4N0-2M0
Patients with dMMR or MSI-H
Presence of other types of tumors in addition to colon adenocarcinoma
Claustrophobia or inability to undergo MRI or treatment due to the presence of metal implants or other reasons
Distant metastasis (M1)